Heard, J.M ;
Vrinten, C ;
Schlander, M...
Heard , J M , Vrinten , C , Schlander , M , Bellettato , C M , van Lingen , C , Scarpa , M , Matthijs , G , Nassogne , M C , Debray , F G , Roland , D , Chamova , T , Kozich , V , Pavel , J , Zenker , M , Lampe , C , Das , A M , Hennermann , J , Kolker , S , Weinhold , N , Mohnike , K , Gruenert , S , Lund , A M , Morales-Conejo , M , del Toro-Riera , M , Aldamiz-Echevarria , L , Garcia-Silva , M T , Schiff , M , Gouya , L , Labrune , P , de Lonlay , P , Belmatoug , N , Germain , D P , Cano , A , Dobbelaere , D , Jones , S , Dawson , C , Deegan , P , Santra , S , Vijay , S , Ramadza , D P , Baric , I , Zigman , T , Pflieger , G , Szakszon , K , Kaposta , R , Gasperini , S , Burlina , A , Parenti , G , Strisciuglio , P , Ceccarini , G , MetabERN collaboration group & Rubio Gozalbo , M E 2020 , ' Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN networ....
,
2020
